Overview
Since December 2019, the novel coronavirus has rapidly spread worldwide, causing a large-scale pandemic.

We are studying and developing a type of recombinant protein vaccine. Compared to traditional inactivated vaccines, recombinant proteins have many advantages, including more security, specificity, immunogenicity, stability, and manufacturing ease.

During the study, we used new resources that could not be found in the Part Register . So we would create some new parts in to  the database. 

 

1.  Create a New Basic Part BBa_K4861000, Wuhan-SARS-CoV2 RBD

BBa_K4861000 is a coding sequence of Wuhan-SARS-CoV2 RBD. The Wuhan strain is one of the strains we used in our research. This code represents a gene segment of the S protein from the Wuhan strain. We conducted tests to evaluate the binding capacity of this protein segment with the human ACE2 protein and achieved significant results.

2.  Create a New Basic Part BBa_K4861001, Delta-SARS-CoV2 RBD

BBa_K4861001 is a coding sequence of Delta-SARS-CoV2 RBD. The Delta strain is one of the strains we used in our research. This code represents a gene segment of the S protein from the Wuhan strain. We conducted tests to evaluate the binding capacity of this protein segment with the human ACE2 protein and achieved significant results.

3.  Create a New Basic Part BBa_K4861002, BQ1.1-SARS-CoV2 RBD

BBa_K4861003 is a coding sequence of BQ1.1-SARS-CoV2 RBD. The BQ1.1 strain is one of the strains we used in our research. This code represents a gene segment of the S protein from the Wuhan strain. We conducted tests to evaluate the binding capacity of this protein segment with the human ACE2 protein and achieved significant results.

4.  Create a New Basic Part BBa_K4861003, XBB1.5-SARS-CoV2 RBD

BBa_K4861000 is a coding sequence of XBB1.5-SARS-CoV2 RBD. The XBB1.5 strain is one of the strains we used in our research. This code represents a gene segment of the S protein from the Wuhan strain. We conducted tests to evaluate the binding capacity of this protein segment with the human ACE2 protein and achieved significant results.

5.  Create a New Composite BBa_K4861008, Wuhan-pET28a.

Wuhan-pET28a is a novel plasmid constructed using the pET-28a vector and a gene fragment Wuhan-SARS-CoV2 RBD. When this plasmid is introduced into BL21 Escherichia coli, it will produce the recombinant protein we need. It can be used to manufacture recombinant protein vaccines for viral strains.

Progress of Combination

First, we extracted the plasmid of pET-28a. Then, we used Nco1 and Xho1 enzymes to cut out two sticky ends on the plasmid (enzyme digestion). Next, we allowed Wuhan-SARS-CoV2 RBD to insert into the cut plasmid and then used T4 ligase to rejoin the plasmid (ligation). Subsequently, the recombined plasmid was transformed into the competent state of Escherichia coli for replication and translation to produce the protein.

 

6.  Create a New Composite BBa_K4861005, Delta-pET28a.

Delta-pET28a is a novel plasmid constructed using the pET-28a vector and a gene fragment Delta-SARS-CoV2 RBD. When this plasmid is introduced into BL21 Escherichia coli, it will produce the recombinant protein we need. It can be used to manufacture recombinant protein vaccines for viral strains.

Progress of Combination

First, we extracted the plasmid of pET-28a. Then, we used Nco1 and Xho1 enzymes to cut out two sticky ends on the plasmid (enzyme digestion). Next, we allowed Delta-SARS-CoV2 RBD to insert into the cut plasmid and then used T4 ligase to rejoin the plasmid (ligation). Subsequently, the recombined plasmid was transformed into the competent state of Escherichia coli for replication and translation to produce the protein.

 

7.  Create a New Composite BBa_K4861006, BQ1.1-pET28a.

BQ1.1-pET28a is a novel plasmid constructed using the pET-28a vector and a gene fragment Delta-SARS-CoV2 RBD. When this plasmid is introduced into BL21 Escherichia coli, it will produce the recombinant protein we need. It can be used to manufacture recombinant protein vaccines for viral strains.

Progress of Combination

First, we extracted the plasmid of pET-28a. Then, we used Nco1 and Xho1 enzymes to cut out two sticky ends on the plasmid (enzyme digestion). Next, we allowed BQ1.1-SARS-CoV2 RBD to insert into the cut plasmid and then used T4 ligase to rejoin the plasmid (ligation). Subsequently, the recombined plasmid was transformed into the competent state of Escherichia coli for replication and translation to produce the protein.

 

8.  Create a New Composite BBa_K4861007, XBB1.5-pET28a.

XBB1.5-pET28a is a novel plasmid constructed using the pET-28a vector and a gene fragment XBB1.5-SARS-CoV2 RBD. When this plasmid is introduced into BL21 Escherichia coli, it will produce the recombinant protein we need. It can be used to manufacture recombinant protein vaccines for viral strains.

Progress of Combination

First, we extracted the plasmid of pET-28a. Then, we used Nco1 and Xho1 enzymes to cut out two sticky ends on the plasmid (enzyme digestion). Next, we allowed XBB1.5-SARS-CoV2 RBD to insert into the cut plasmid and then used T4 ligase to rejoin the plasmid (ligation). Subsequently, the recombined plasmid was transformed into the competent state of Escherichia coli for replication and translation to produce the protein.